Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxaprozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 19/20 | 1.00 |
| ▸ | RXRB | P28702 | 19/20 | 1.00 |
| ▸ | RXRG | P48443 | 15/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | C5 | P01031 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxaprozin SCHEMBL8191237 | 1.00 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL3849972 | 1.00 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL8191554 | 0.98 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL8190680 | 0.98 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL5732754 | 0.98 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL137988 | 0.98 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL6380181 | 0.98 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL28469762 | 0.98 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL10968776 | 0.97 | RXRA (0.94) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL8607424 | 0.96 | RXRA (0.91) | RXRARXRBRXRGNR4A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 54490 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260132191-A1 | METHODS FOR MODULATING ACTIVITY OF IL-18 FOR TREATMENT OF CD4+ T CELL MEDIATED AUTOIMMUNITY AND IMMUNOPATHOLOGY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-3917993-B1 | MULTI-COAT POLYMER PHOTONIC CRYSTAL FILMS | UNIV COLORADO STATE RES FOUND (US) | 2026-05-13 | — | — | EP | claimed |
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122004216-A | Herbicide composition containing cyclohexene diketone lactic acid oxime ether derivative and application thereof | 郑州手性药物研究院有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-1985004589-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | SUNSHINE ABRAHAM | 1985-10-24 | — | — | WO | claimed |
| EP-0063884-B1 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND USE | JOHN WYETH & BROTHER LIMITED (GB) | 1985-06-26 | — | — | EP | claimed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | claimed |
| US-4522826-A | SYNERGISTIC MIXTURES | RICHARDSON-VICKS INC. (US) | 1985-06-11 | — | — | US | claimed |
| US-4486436-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | ANALGESIC ASSOCIATES (US) | 1984-12-04 | — | — | US | claimed |
| EP-0114886-A1 | IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE. | SUNSHINE ABRAHAM (US) | 1984-08-08 | — | — | EP | claimed |
| WO-1984002273-A1 | ANALGESIC COMBINATIONS | SANDOZ AG (CH) | 1984-06-21 | — | — | WO | claimed |
| EP-0111456-A1 | Analgesic combinations | Cooper, Stephen A. Dr. (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1984000490-A1 | IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1984-02-16 | — | — | WO | claimed |
| EP-0063884-A1 | Oxazole derivatives, their preparation and use | JOHN WYETH & BROTHER LIMITED (GB) | 1982-11-03 | — | — | EP | claimed |